AdaptVac aims to accelerate the development of safe and efficacious therapeutic and prophylactic vaccines to treat and prevent specific cancers, infectious diseases and immunological disorders. AdaptVac, as part of the EU H2020 funded PREVENT-nCoV consortium, is currently focused on developing a SARS-CoV-2 (COVID-19) vaccine using its capsid Virus-Like Particle (VLP) display technology.
AdaptVac is a joint-venture between NASDAQ First North listed ExpreS2ion Biotech and University of Copenhagen spin-out NextGen Vaccines, lead by CEO Wian De Jongh and CSO Adam Sander. The company is based in Horsholm, Denmark, and joined NOME in 2020.